WuXi AppTec Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From WuXi AppTec Inc.
The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
Takeda pursues RNA-targeting R&D with Evotec and Anima, looks into liver disease with Genevant. Plus deals involving Kyowa Kirin/Twist, Bright Peak/Ajinimoto & Torii/Verrica.
Experts share what they believe are the solutions to key manufacturing challenges, such as lowering cost of goods and centralized manufacturing, in the cell and gene therapy sector.
- Contract Research, Toxicology Testing-CRO
- Medical Devices